Drug notes:
FT-001 Clin1 LCA2; FT-002 Clin1 X-linked retinitis pigmentosa; FT-004 Clin0 Hemophilia B; 4 add'l early stage products
About:
Frontera Therapeutics is developing cost-effective recombinant virus-based gene therapies across multiple disease areas. Using their APEX technology and manufacturing platform, Frontera is creating adeno-associated virus (AAV) gene expression systems to develop novel gene therapy products with quicker speed-to-market and lower cost. With their advanced technology, Frontera is building a pipeline that extends beyond monogenic diseases to indications in Ophthalmology, Hematology and Cardiovascular and Metabolic Diseases.